QNRX

QNRX

USD

Quoin Pharmaceuticals Ltd. American Depositary Shares

$9.860-0.283 (-2.791%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$10.143

Máximo

$10.500

Mínimo

$9.860

Volumen

0.01M

Fundamentos de la Empresa

Capitalización de Mercado

5.9M

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

0.31M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $5.01Actual $9.860Máximo $48.3

Noticias Relacionadas

GlobeNewswire

Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025

ASHBURN, Va., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan

Ver más
Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025
GlobeNewswire

Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month 'Whole Body' Data Update from Ongoing Study

Recruitment of Three Additional Pediatric Patients in Austria and Ireland Achieves Investigator Study TargetCurrent Pediatric Patient in Ongoing Study Has Completely Healed Skin After 9 months of ‘Whole Body'

Ver más
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month 'Whole Body' Data Update from Ongoing Study
GlobeNewswire

Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Upon Approval of NDA Quoin Will Receive Seven Years Marketing Exclusivity for QRX003 in the US Orphan Drug Designation previously granted by the European Medicines Agency in May 2025 ASHBURN, Va., Oct. 21, 2025

Ver más
Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome
GlobeNewswire

Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

ASHBURN, Va., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today

Ver más
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.